StockLab Reports: Of Mice and Men

Las Vegas, NV -- November 26, 2018 -- InvestorsHub NewsWire -- Early stage biotechnology and pharmaceutical companies often present a quandary for investors. The technology is generally difficult to understand and investors just can't fully picture the potential.
Except when that picture is an absolutely stunning, must-see video  from Wake Forest University of a mouse paralyzed by Acute Lymphoblastic Leukemia restored to mobility in two days by a drug now headed to the patent portfolio of Spherix Incorporated (Nasdaq: SPEX). The drug, "KPC34," is a next generation treatment designed to overcome multiple resistance challenges and is also administered orally, which is critical for patients who cannot tolerate repeated cycles of chemotherapy. Importantly, the Company reports that the drug has doubled the mean survival time  of patients versus the current standard of care treatments.
Read that again. Doubled.

The brief video is jaw-dropping to say the least and helps affirm the recent merger agreement of Spherix and CBM BioPharma Inc, the private pharma company which obtains exclusive drug development rights of drugs like KPC34 from top-flight partners like Wake Forest University and the University of Texas at Austin.  Spherix and CBM agreed to merge earlier this month.

The merger will put the all-new Spherix right in the middle of a rapidly expanding oncological drug market that pharma industry publication DCAT Value Chain Insights reports topped $133 billion globally in 2017, and with spending on cancer drugs having doubled in the United States since 2012. (Source:  DCAT Value Chain Insights)

The same report also cites the IQVIA Institute for Human Data Science  which projects a global market for oncology therapeutic medicines reaching $200 billion by 2022, averaging 10% to 13% growth during that time while the U.S. market is expected to reach $100 billion with an average growth rate of 12% to 15% for the same period. Additionally, spending on cancer drugs in the U.S. is expected to double by 2022, exceeding the nearly $50 billion in spending in 2017.

It warrants mention that Spherix is also aggressively pursuing opportunities in the arena of pancreatic cancer via another CBM project that will be added through the merger. Developed at the University of Texas at Austin, the drug DHA-dFdC has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs.

And while the mouse video is head turning, inspiring even, it is potentially the tip of the iceberg for a company which has come so very far, both in its science and in the enormous increase of intellectual property now headed inside the deal. Ultimately, Spherix's true value is unlikely to be fully recognized until it has successfully changed oncological care outcomes for mice andmen.

About Spherix
Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. Spherix has acquired over 100 patents from Rockstar Consortium Inc., and several hundred patents issued to Harris Corporation, covering a variety of methods and components involved in switching, routing, networking, optical and telecommunication sectors. The Spherix/CBM merger is pending approval.

About CBM BioPharma, Inc.
CBM BioPharma, Inc. (www.cbmbiopharmainc.com ) is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas at Austin. The Company has a team of leading drug development scientists who help advance their technology. The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and pancreatic cancer.

About StockLab:
StockLab is powered by professional journalists with two-decades of experience in public markets. Each subject company that StockLab is contracted to cover is examined through a macro/micro approach that reviews larger events for its primary industry and how it might affect future market opportunities. First tier sources will be studied, cited, and offered to readers. Additionally, material events by the subject company will be noted for the readers' consideration. We often rely on industry experts, Forbes, Bloomberg, The Wall Street Journal and other periodicals of established pedigree which have no relationship to the covered company whatsoever.
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. StockLab is the property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject company has reviewed and approved this report. This report is neither a solicitation to buy nor offer to sell securities and is for informational purposes only and shouldn't be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. IMI has been paid $1,500 for this report by Hayden IR on behalf of and for the benefit of Spherix Incorporated. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies. Other articles linked to herein have not been individually vetted for accuracy.

To have your company featured in a StockLab report please use the contact info below:
Integrity Media
www.StockLab.com & 
www.IntegrityIR.com
info@integrityir.com
(888) 216-3595



https://www.smarteranalyst.com/brief/the-ceo-of-spherix-inc-spex-is-buying-shares/


 

Disclaimer

What is the Nature of the Information We Distribute?
Emerging Markets Consulting, LLC ("EMC"), its principals, affiliates, representatives, subcontractors or agents (hereafter referred to as "EMC" or "we" or "us") prepare and/or assist others in preparing and publishing oral and written information about public companies ( referred to herein individually as the "Profiled Company" ) and their securities (the "Securities"), including corporate and business profiles, alerts, summaries, reports, and press releases (hereafter referred to as the "Information") through: (a) double opt-in spam compliant emails; (c) mail and courier; (d) EMC's websites profiling the Profiled Company; and (e) otherwise through the worldwide web. In certain cases, we are merely a distributor of such publications, i.e. a Profiled Company's press release.

Nature of the Information
We generally only provide favorable information and no negative information; thus, the Information is incomplete and we urge you to avail yourself of all reliable sources of information, including sec.gov, otcmarkets.com and Google.

Due Diligence?
We conduct no due diligence regarding the Information.

What we are Not
We are not independent and the Information should be construed as a paid advertisement. We do not conduct research or evaluate if the Information is true, accurate or complete. The Information should not be construed as a recommendation to purchase or sell the securities of the Profiled Company or as providing any information that may be construed as investment advice. We are not and do not act in the capacity of: (a) an investment advisor; (b) a stock picker; (c) a securities trading expert; (d) a securities analyst; (e) a financial analyst; (f) one that provides stock recommendations, price targets, buy, sell or hold recommendations. Rather, we only introduce a company to the readers of our publications as a starting point for investigating the securities and the Profiled Company through publicly available sources. EMC does not endorse, independently verify, or assert the truthfulness, completeness, accuracy or reliability of the Information; as such, the Information is presented in an "as is" format and the Recipients should not rely on the data or information contained in the Information in making an investment decision and should conduct their own research of the Profiled Company.

Beware of Revenue Projections
The Recipients of the Information should be especially cautious about any revenue predictions, projected revenues, revenue expectations or revenue estimates (the "Revenue Projections") because: (a) we conduct no due diligence whatsoever on whether the Revenue Projections have a foundational basis; (b) the Revenue Projections may not be in accordance with US Generally Accepted Accounting Principles or SEC guidelines for projections; (c) the assumptions upon which the projections are being made may lack a foundational basis; (d)) the Revenue Projections may be inherently unreliable because they are subject to future events.

Cautionary Advice on Use of the Information
The Information is disseminated to broker-dealers, members of the public, readers of our website, and the financial community (collectively the "Recipients") at the direction of the Profiled Company or other investor relations firms or third-party shareholders of the Profiled Company or firm hired by the Profiled Company for which we provide subcontracting services or through social media, including Facebook, Twitter, LinkedIn and blog spots. The Information should only be used by as a beginning point for further investigation into the Profiled Company and its securities because EMC: (a) only presents neutral or positive information regarding the Profiled Company and its business; (b) does not present the risks or negative aspects associated with the Profiled Company or its securities; and (c) the Information is wholly inadequate to formulate any investment decision. As such, we strongly advise against making any investment decisions solely based on the Information. It is imperative that you consult with your professional advisor, financial adviser, financial planner, registered broker or attorney regarding the advisability of investing in any securities, especially penny stocks. In addition, you should consult with government or other websites that are available free of charge at www.sec.gov, www.otcmarkets.com, Google, or other sources that offer specific business and financial information about the Profiled Company, investment guides and valuable information pertaining to penny stocks, penny stock frauds and penny stock investment risks. Where applicable, you should review the quarterly (Form 10-Q) and annual (Form 10-K) financial and disclosure reports available at www.sec.gov. For those companies that are not SEC reporting companies, you should review the quarterly and annual reports available for your review at www.otcmarkets.com.

Payment for our Services
We are paid for our services in either money or securities or a combination of cash and securities compensation. The publicly traded companies or third-party shareholders or other publishers or investor relations firms that subcontract with us for the services that they have directly contracted for with a publicly traded company or a third-party shareholder pay us for our advertisements

Our Trading Activities
Pursuant to an agreement between EMC and a Profiled Company, EMC always receives compensation from the Profiled Company or third-party shareholder or other investor relations firm in cash and/or securities compensation of the Profiled Company for the services that EMC performs in connection with preparation and/or dissemination of the Information, EMC regularly and routinely sells the Profiled Company's securities before, during and after its dissemination of the Information regarding the Profiled Company (most frequently during the dissemination of the Information), which may result in substantial profits to EMC. EMC may purchase shares of the Profiled Company before, during and after dissemination of the Information disseminated by EMC, which may result in substantial profits to EMC. ; EMC's dissemination of the Information may result in increases in the Profiled Company's securities total trading volume or in the purchase volume of the Profiled Company's securities, enabling EMC to sell its Securities at a profit from the securities compensation it receives for providing services involving publications of the Profiled Company. EMC's sale of the Profiled Company's securities concurrently with the dissemination of the Information, including the Profiled Company's profile, may enable EMC to sell at a higher price for such shares, and may result in a diminished value to those buying the Profiled Company's securities because of EMC’s selling activities

Conflicts of Interest
Our advertisements involve an actual conflict of interest, since we receive compensation in the very securities we are promoting and then sell the securities during our advertorial activities or thereafter. The Profiled Company or investor relations firm or third-party shareholder from whom we receive compensation also has an actual conflict of interest since they pay us securities compensation for advertising services and then may sell their own shares of the Profiled Company while we are publishing the Information about the Profiled Company or its securities

Forward Looking Statements
Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties and may be identified using terminology such as "believes", "expects", "may", ""will", or "should"", or "anticipates". Such statements should be read as being applicable to all related forward looking statements wherever they appear in any of the Information. The actual results of a Profiled Company's operations, financial condition or other aspects of its business could differ materially from those discussed in the Information.

No Warranties
We do not make any implied or express warranties regarding the Information -- you should not solely rely upon the Information; rather, again you should use the Information and/or its securities as an initial introduction to the Profiled Company to initiate an investigation into a Profiled Company through, among other sources, information and reports available at the above-listed websites.
Risks
Use of the Information as well as any investment in micro-cap or penny stock securities is subject to the following risks:
  • EMC is not a registered investment advisor or registered securities broker dealer and no information contained within the Information should be construed as investment advice or as a solicitation to offer, purchase or sell the Securities; therefore, you should never use the Information as the only basis upon which you make an investment decision and understand that the use of our Information does not provide you with the benefits of receiving advice from a registered investment adviser or registered representative or a broker or dealer and/or conducting an in-depth investigation of a Profiled Company.
  • EMC does not provide stock recommendations; as such, none of the Information should be construed directly or indirectly or explicitly or impliedly, as stock recommendations and you should rely upon your professional adviser regarding such matters, including your registered broker, investment adviser or other qualified financial adviser.
  • EMC does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Company.
  • Penny stocks are subject to the SEC's penny stock rules, which may cause difficulties in liquidating micro-cap securities;
  • Penny stocks by their very nature involve a high degree of risk and may involve the loss of one's entire investment.
  • Energy, biotech, and other companies are subject to increased regulations, which subject them to material costs and possible fines and liabilities.
  • Because we may sell material amounts of the Securities during the dissemination of the Information, shortly thereafter, or at any time, our selling activities may negatively cause price volatility, stock price declines and/or increased/decreased selling volume.
  • Because we may purchase material amounts of the Securities in the open market before, during or after the dissemination of the Information, such activities may cause price volatility, stock price increases or declines or increased/decreased volume.
  • Because we only present positive or neutral information regarding the Profiled Company and do not provide negative information in our Profiles, it is all the more important that you conduct further investigation of the Profiled Company, consult with outside sources (i.e. www.sec.gov) and consult with your professional adviser. Additionally, because we only present selected positive or neutral information, when conducting your investigation into the Profiled Company and its securities you should determine what information is material or immaterial.
  • Because EMC is a Shareholder of the Profiled Company, it has an inherent conflict of interest with the Recipients, wherein EMC may favor their own interests over that of the Recipients because EMC may be selling its own securities of the Profiled Company during its publication and/or distribution of the Information or at any time.
  • The buying and selling of the Securities by EMC may negatively affect the volume or price of the Securities, including price declines or price and volume volatility.
  • Penny stock securities are often thinly traded, in which case you may have difficulties in liquidating your securities.
  • Penny stock securities by their very nature involve an extremely high degree of risk.
  • Because the Securities are penny stocks they are subject to the Securities and Exchange Commission's penny stock rules; as such, any investment in the Securities involves a high degree of risk and it may be difficult for any investor or Shareholder to resell the Securities.
  • An investment in the Profiled Company's Securities could result in the loss of some or all an investment in the Profiled Company's Securities.
  • The issuance of the Securities to EMC may cause shareholders and/or investors of the Profiled Company to experience immediate and substantial dilution of their holdings and/or investments in the Profiled Company
  • Future securities issuances to EMC for services may also result in a reduction of (i) the book value or market price of the Profiled Company's securities, (ii) shareholder voting power; and (iii) each shareholder's proportionate ownership of any Profiled Company.
  • You should consider whether the Profiled Company is a development stage company or has little or no operations or no revenues or assets, the conditions of which may increase the risk investment level of investing in the Profiled Company.
  • You should consider the financial condition of the Profiled Company in your analysis by accessing such information from www.sec.gov or www.otcmarkets.com; if such financial information is unavailable from either one of these sites, the risk investment level of investing in any such Profiled Company will be increased.
  • Many of the companies are subject to numerous risks particular to the industry that they engage in.
  • We conduct no due diligence whatsoever regarding: (a) the Issuer; (b) the third-party shareholder; and (c) the relationship, if any, between the third-party shareholder and the Issuer;
  • Our trading activities described above may cause: (a) significant volatility in the Issuer's; (b) price declines from our selling activities; (c) an unrealistic report of trading volume, without denoting publicly that we are the primary seller; (d) permit us to make substantial profits while we are disseminating profiles or information about the issuer, yet may result in a diminished value of the Profiled Company's Securities
  • We conduct no due diligence on the press releases or profiles we receive from OTC Markets News Service or other publicly available source, nor do we conduct due diligence on any other information we disseminate to the public.
  • Penny stocks are subject to the SEC's penny stock rules and subject broker-dealers to customer suitability rules and other requirements, which may lead to low volume in the securities and/or difficulties in selling the shares.
  • Many of the stocks of the Profiled Company qualify as "penny stocks" under the Securities and Exchange Commission's ("SEC") penny stock rules and regulations because, among other things, they have a price of less than $5.00 per share. Penny stocks are subject to material risks that you should be acutely aware of, as detailed below.
  • We do not assume any responsibility for forward-looking statements nor do we assume any responsibility for updating forward-looking statements
  • Use of this information is at your own risk and is presented only on an "as is" basis - in other words, you must conduct your own analysis of the risks associated with use of the Information, including its accuracy or reliability
  • Many penny stocks are thinly traded, which may lead to difficulties in selling your securities and extreme price volatility.
  • Penny stock companies are often subject to extreme regulatory oversight in the industry that they participate in.
  • Penny stock companies are often subject to extreme competition and most frequently have less brand name recognition, operational and personnel resources, technical resources, capital resources, or financing sources.
  • There is no "right time" to purchase or sell penny stocks or set of factors making it advisable to purchase a Profiled Company's securities "now", since at any time such stocks may be subject to price volatility, stock manipulation forces and other negative market forces.
  • A Profiled Company may have negative signs on the otcmarkets.com website that indicate various risks of investing in that individual issuer, as follows: (i) "Limited Information" for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) "Pink Sheets - No Information", which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) "Caveat Emptor", signifying "Buyer Beware" that there is a public interest concern associated with a company's illegal spam campaign, questionable stock promotion, known investigation of a company's fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
  • The Issuer may be delinquent in its filings with the Securities and Exchange Commission or at otcmarkets.com, which you will be able to determine by accessing the websites at www.sec.gov or www.otcmarkets.com.
  • The stock price and trading volume of any Issuer that we advertise may increase significantly because of our dissemination of the Information and then significantly decrease because of our or others selling significant or massive quantities of an Issuer;
  • Many penny stock companies are subject to risks pertaining to the development stage nature of their business, including that they have failed to provide a proof of concept to their technology or business or their business plan has little if any merit whatsoever.
  • Many penny stock companies need financing, which they may be unable to obtain on favorable terms or at all.
  • Our advertising activities may cause trading volume of a Profiled Company's securities to temporarily increase by hundreds or thousands of percent, yet such trading volume may cease at any one time;
  • Our advertising activities may cause trading volume in Issuers to materially increase, yet such trading volume may cease at any one time, especially if we cease disseminating Information about the Issuers, which will cause difficulties in selling your securities or may be an unrealistic indicator of interest in the Issuer's securities.
  • The Information has no predictive value whatsoever of the future stock price of the Profiled Company's securities or its ability to be successful in its business objectives.
  • Should the SEC determine that inadequate information or irregularities have occurred with a Penny Stock Issuer, they may issue a trading suspension, which will suspend trading in the Issuer's securities and may for all intents and purposes permanently cease trading because broker-dealers may not accept trades in that Issuer’s securities.
  • The press releases, issuer profiles and information we provide represent only a small amount of information regarding the Issuer, which is insufficient to formulate an investment decision; as such, that information should only be a starting point from which you conduct an in-depth investigation of the issuer from available public sources, such as www.sec.gov, www.otcmarkets.com, yahoofinance.com, www.google.com and other available public sources; and
 
Conduct an In-Depth Investigation
You should conduct an in-depth investigation of the Profiled Company and its securities from the above or any other credible available sources, especially because we only present positive information and limited specific information which is an insufficient basis to invest in any stock, yet alone a penny stock; accordingly, you should proceed with an investigation to determine, among other things, information pertaining to the issuer's financial condition, operations, business model, and risks involved in the issuer's business.

Compensation Disclosure
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
EMC has been paid $35,000 from Spherix Inc,
 
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alkido Pharma Charts.
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alkido Pharma Charts.